Paclitaxel - Bristol-Myers Squibb

Drug Profile

Paclitaxel - Bristol-Myers Squibb

Alternative Names: BMS-181339; BMY 45622; NSC-673089; Taxol

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Bristol-Myers Squibb
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Kaposi's sarcoma; Non-small cell lung cancer; Ovarian cancer
  • Phase II Head and neck cancer
  • Discontinued Bladder cancer; Cancer metastases; Cervical cancer; Endometrial cancer; Leukaemia; Lung cancer; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Pleural effusion; Prostate cancer; Sarcoma; Small cell lung cancer; Testicular cancer

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 17 Mar 2005 Registered as adjuvant treatment for early stage node-positive breast cancer in European Union under the mutual recognition procedure; the Netherlands acted as the reference member state (IV-infusion)
  • 30 Sep 2004 Phase-III clinical trials in Cervical cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top